Why TIER IV Is Backing a Taiwan Startup to Push Autonomous Driving Forward

Autonomous driving is often discussed in terms of futuristic cars and distant timelines. This investment is about something more immediate. Japan-based TIER IV has invested in Turing Drive, a Taiwan startup that builds autonomous driving systems designed for controlled, everyday environments such as factories, ports, airports and industrial campuses. The investment establishes a capital and business alliance between the two companies, with a shared focus on developing autonomous driving technology and expanding operations across Asia.

Rather than targeting open roads and city traffic, Turing Drive’s work centres on places where vehicles follow fixed routes and move at low speeds. These include logistics hubs, manufacturing facilities and commercial sites where automation is already part of daily operations. According to the release, Turing Drive has deployments across Taiwan, Japan and other regions and works closely with vehicle manufacturers to integrate autonomous systems into special-purpose vehicles.

The investment also connects Turing Drive more closely with Autoware, an open-source autonomous driving software ecosystem supported by TIER IV. Turing Drive joined the Autoware Foundation in September 2024 and develops its systems using this shared software framework. TIER IV’s own Pilot.Auto platform, which is built around Autoware, is used across applications such as factory transport, public transit, freight movement and autonomous mobility services.

Through the alliance, TIER IV plans to work with Turing Drive to further develop autonomous driving systems for these controlled environments, while strengthening its presence in Taiwan and the broader Asia-Pacific region. The collaboration brings together software development and on-the-ground deployment experience within markets where autonomous driving is already being tested in real operational settings.

“This partnership with Turing Drive represents a significant step forward in accelerating the deployment of autonomous driving across Asia”, said TIER IV CEO Shinpei Kato. “At TIER IV, our mission has always been to make autonomous driving accessible to all. By collaborating with Turing Drive, which has demonstrated remarkable achievements in real-world deployments in Taiwan, we aim to deliver autonomous driving that enables a safer, more sustainable and more inclusive society”.

“We are thrilled to establish this strategic alliance with TIER IV, a global leader in open-source autonomous driving”, said Weilung Chen, chairman of Turing Drive. “In Taiwan, autonomous driving deployment is gaining significant momentum, particularly across logistics hubs, ports, airports and industrial campuses. By combining our field expertise with TIER IV's world-class Pilot.Auto platform, we aim to accelerate the development of practical, commercially viable mobility services powered by autonomous driving”. Overall, the investment highlights how autonomous driving in Asia is being shaped by operational needs and gradual integration, rather than headline-grabbing demonstrations.

Keep Reading

Biotechnology

OpenAI and Top Investors Back Valthos with US$30M to Advance AI-Driven Biodefense

Reimagining biodefense at the intersection of AI, biology and urgency.

Ventureport Media Team

Updated

November 27, 2025 3:26 PM

Through computational tools, Valthos analyzes biological data to design adaptive solutions against emerging threats. PHOTO: VALTHOS

Valthos has raised US$30 million in seed funding, led by the OpenAI Startup Fund, Lux Capital and Founders Fund, to advance its mission of building next-generation biodefense systems.

The company’s work comes at a time when biotechnology is evolving at an unprecedented pace. Biotechnology is moving at record speed. These new tools can lead to life-changing medical discoveries, but they also bring the risk of dangerous biological agents being developed faster than ever.

“The issue at the core of biodefense is asymmetry”, said Kathleen McMahon, co-founder of Valthos. “It’s easier to make a pathogen than a cure. We’re building tools to help experts at the frontlines of biodefense move as fast as the threats they face”. The gap Valthos aims to close is between the rapid rise of biological threats and the slower pace of developing cures. Therefore, the company is developing AI systems that can rapidly analyze biological sequences and significantly shorten the time needed to design medical countermeasures.

“In this new world, the only way forward is to be faster. So we set out to build a new tech stack for biodefense”, said Tess van Stekelenburg, co-founder of Valthos. “This software infrastructure strengthens biodefense today and lays the groundwork for the adaptive, precision therapeutics of tomorrow”.

The company was founded by van Stekelenburg, a partner at Lux Capital and McMahon, the former head of Palantir’s Life Sciences division. Together, they’ve built a multidisciplinary team of experts from Palantir, DeepMind, Stanford’s Arc Institute and MIT’s Broad Institute, bringing together deep experience in software engineering, machine learning and biotechnology.

“Technology is moving fast. An industrial ecosystem of builders, companies and solutions further democratizes AI to provide broad resilience, and ensures the U.S. continues to lead as AI increasingly powers everything around us. As AI and biotech rapidly advance, biodefense is one of the new industry verticals that helps maximize the benefits and minimize the risks”, said Jason Kwon, OpenAI’s Chief Strategy Officer. “Valthos is pushing the frontier of protection and defense in one of the most strategic intersections of multiple world-changing technologies, and with the team to do it”.

Looking ahead, Valthos plans to expand its engineering team and scale its software infrastructure for both government and commercial partners — moving closer to its goal of enabling faster, smarter and more adaptive biodefense capabilities.

Business